2024 Annual Meeting | C105 - Alzheimer's Disease

Date Tuesday 04/16/24

Time 07:00 AM - 09:00 AM MDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Liliana A. Ramirez-Gomez, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives During this course, participants will be introduced to the concept of AD as a clinicopathologic entity and explain approaches to detect AD early in the disease continuum; discuss the range of biomarker breakthroughs to detect AD, including blood base, CSF, and neuroimaging biomarkers, and the role of these tools in research and clinical practice; discuss the importance of integrating clinical assessment and biomarkers to obtain an early diagnosis; recognize and understand the clinical heterogeneity in AD; discuss the most recent therapeutic advances and emerging therapies for Alzheimer's disease and discuss the Appropriate Use Recommendations for monoclonal antibodies and its implementation in clinical practice.

This program is supported in part by educational grants from Lilly and Eisai Inc.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator

Teaching Styles Didactic

Program Evaluations

Event Timeline
07:00 AM - 07:05 AM MDT	Introduction	Welcome and Introductions Liliana A. Ramirez-Gomez, MD, FAAN
07:05 AM - 07:40 AM MDT	Speaker	The Use of Biomarkers for the Diagnosis and Staging of Alzheimer’s Disease Julio C. Rojas-Martinez, MD, PhD
07:40 AM - 08:10 AM MDT	Speaker	Emerging Therapies for the Treatment of Alzheimer’s Disease Jeremy J. Pruzin, MD
08:10 AM - 08:40 AM MDT	Speaker	Implementation of Newly Approved Disease-modifying Therapies for Alzheimer’s Disease in Clinical Practice Liliana A. Ramirez-Gomez, MD, FAAN
08:40 AM - 09:00 AM MDT	Discussion	Questions & Answers Julio C. Rojas-Martinez, MD, PhD, Liliana A. Ramirez-Gomez, MD, FAAN, Jeremy J. Pruzin, MD

Faculty Disclosures
Liliana A. Ramirez-Gomez, MD, FAAN	The institution of Dr. Ramirez-Gomez has received research support from NIA-NIH.
Jeremy J. Pruzin, MD	Dr. Pruzin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedNet. Dr. Pruzin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Synapticure. The institution of Dr. Pruzin has received research support from NIA.
Julio C. Rojas-Martinez, MD, PhD	Dr. Rojas-Martinez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ferrer International, S.A.. The institution of Dr. Rojas-Martinez has received research support from NIH/NIA. The institution of Dr. Rojas-Martinez has received research support from Eli Lilly. The institution of Dr. Rojas-Martinez has received research support from Eisai. The institution of Dr. Rojas-Martinez has received research support from Amylyx.

��ɫ��

��ɫ��